Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 1
- Registration Number
- NCT05207722
- Locations
- 🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Scripps Health, La Jolla, California, United States
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- LLS PedAL Initiative, LLC
- Target Recruit Count
- 98
- Registration Number
- NCT05183035
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Alliance for Childhood Diseases dba Cure 4 The Kids Foundation, Las Vegas, Nevada, United States
FT576 in Subjects With Multiple Myeloma
- Conditions
- Multiple MyelomaMyeloma
- Interventions
- Drug: FT576 (Allogenic CAR NK cells with BCMA expression)Drug: CyclophosphamideDrug: FludarabineDrug: BendamustineDrug: Daratumumab
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT05182073
- Locations
- 🇺🇸
Texas Oncology-Medical City Dallas, Dallas, Texas, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
- Conditions
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Stage IV MelanomaLocally Advanced MelanomaPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- Drug: CyclophosphamideDrug: FludarabineBiological: LifileucelBiological: PembrolizumabProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Richard Wu
- Target Recruit Count
- 2
- Registration Number
- NCT05176470
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Conditions
- T-lymphoblastic LymphomaAcute Biphenotypic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaAcute LeukemiaAcute Undifferentiated LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: CyclophosphamideDrug: FludarabineRadiation: Total Body IrradiationDrug: BusulfanDrug: MesnaDrug: SirolimusDrug: Mycophenolate MofetilDrug: FilgrastimProcedure: Bone Marrow Transplant
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ossium Health, Inc.
- Registration Number
- NCT05170828
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
- Conditions
- LymphomaNeoplasmsLymphoma, Mantle-CellNeoplasms by Histologic TypeLymphoproliferative Disorders
- Interventions
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05155215
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Mixed Phenotype Acute LeukemiaDown SyndromeMyelodysplastic Syndrome Post Cytotoxic TherapyRecurrent Mixed Phenotype Acute Leukemia
- Interventions
- Drug: CytarabineDrug: FludarabineDrug: LeucovorinDrug: Triple Intrathecal ChemotherapyDrug: Uproleselan
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT05146739
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Conditions
- Myelodysplastic SyndromeAcute Lymphoblastic LeukemiaSecondary Acute Myeloid LeukemiaAcute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: BasiliximabDrug: Fludarabine PhosphateDrug: Indium In 111-DOTA-BasiliximabDrug: MelphalanBiological: PaliferminRadiation: Total Lymphoid IrradiationRadiation: Total Marrow IrradiationBiological: Yttrium Y 90 Basiliximab
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05139004
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL
- Conditions
- Lymphoma Leukemia
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT05114837
- Locations
- 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
- Conditions
- Myeloid MalignanciesAcute Myeloid LeukemiaChronic Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- Drug: MesnaDrug: Fludarabine phosphateDrug: CyclophosphamideDrug: MelphalanDrug: FilgrastimDrug: TacrolimusDrug: Mycophenolate mofetilDrug: Total Body Irradiation One Dose
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05115630
- Locations
- 🇺🇸
M D Anderson Caner Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.